![Albert Bressand](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Albert Bressand
Director/Board Member at Rarecells Diagnostics SAS
Albert Bressand active positions
Companies | Position | Start | End |
---|---|---|---|
Rarecells Diagnostics SAS
![]() Rarecells Diagnostics SAS Packaged SoftwareTechnology Services Rarecells Diagnostics SAS is a French company passionate about saving lives by detecting and eliminating cancer at its start. The company is based in Paris, France and was founded by Patrizia Paterlini-Bréchot, who has been the CEO since incorporation. The company believes that accurate, early cancer detection has the potential to save millions of lives. Rarecells Diagnostics has developed the ISET blood filtration technology, which enables cell culture to generate xenograph of avatars. The company is currently conducting three clinical studies to evaluate the performance of their dedicated ISET-based assay to allow early detection of prostate cancer. The company is also developing a multi-cancer test for early cancer diagnosis and is working with researchers to propel care forward. | Director/Board Member | - | - |
Career history of Albert Bressand
Statistics
International
France | 2 |
Operational
Director/Board Member | 1 |
Sectoral
Technology Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 1 |
---|---|
Rarecells Diagnostics SAS
![]() Rarecells Diagnostics SAS Packaged SoftwareTechnology Services Rarecells Diagnostics SAS is a French company passionate about saving lives by detecting and eliminating cancer at its start. The company is based in Paris, France and was founded by Patrizia Paterlini-Bréchot, who has been the CEO since incorporation. The company believes that accurate, early cancer detection has the potential to save millions of lives. Rarecells Diagnostics has developed the ISET blood filtration technology, which enables cell culture to generate xenograph of avatars. The company is currently conducting three clinical studies to evaluate the performance of their dedicated ISET-based assay to allow early detection of prostate cancer. The company is also developing a multi-cancer test for early cancer diagnosis and is working with researchers to propel care forward. | Technology Services |
- Stock Market
- Insiders
- Albert Bressand
- Experience